Small studies have found that B-cell depletion with rituximab may be beneficial in refractory antineutrophil cytoplasmic antibody-associated (ANCA-associated) vasculitis, due to the presence of ...
Long-Term Follow-Up of Rituximab Maintenance in Young Patients With Mantle-Cell Lymphoma Included in the LYMA Trial: A LYSA Study Clinical trials frequently include multiple end points that mature at ...
Rituximab is a chimeric mouse–human monoclonal antibody (mAb) that targets the B-cell surface marker CD20 with high affinity. CD20 expression spans the developmental stages from the pre-B cell until ...
Belimumab and rituximab demonstrated promise as potential treatments for both refractory and severe childhood systemic lupus erythematosus. Belimumab and rituximab demonstrated promise as potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback